# Halozyme Therapeutics, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Halozyme Therapeutics, Inc). ## Overview Halozyme Therapeutics is a biopharmaceutical company built around drug-delivery technologies rather than a broad portfolio of branded medicines. It licenses ENHANZE, based on the proprietary enzyme rHuPH20, to help partners deliver injected therapies subcutaneously, and it also develops and commercializes auto-injector and combination-device products such as XYOSTED and Hylenex recombinant. ## Products & services • ENHANZE drug-delivery technology using rHuPH20 • Bulk rHuPH20 sales to pharma partners • Royalties and milestones from partnered SC products • Hylenex recombinant for hospital/surgery-center use • XYOSTED testosterone auto-injector product • Auto-injector device development and manufacturing - **ENHANZE licensing and royalties** (55%) — Licenses the ENHANZE platform and earns upfront fees, milestones, bulk rHuPH20 sales and royalties. - **Bulk rHuPH20 supply** (18%) — Commercial supply of the proprietary enzyme used in partner subcutaneous formulations. - **Proprietary product sales** (20%) — Sales of Halozyme-owned products, mainly Hylenex recombinant and XYOSTED. - **Device partnered product sales** (7%) — Sales tied to auto-injector collaborations and related device commercialization. - ENHANZE subcutaneous drug-delivery platform - Bulk rHuPH20 supply for partner formulations - Royalty and milestone income from partnered products - Hylenex recombinant for hospital and surgical settings - XYOSTED testosterone auto-injector - Auto-injector device development, assembly and packaging ## Customers Halozyme sells primarily to biopharmaceutical partners that want to convert injectable drugs into subcutaneous products with better convenience and patient experience. It also sells directly into the U.S. pharmaceutical distribution channel for its proprietary products, serving wholesalers, specialty pharmacies, hospitals, surgery centers, the Veterans Administration and other government buyers. - **Biopharmaceutical collaboration partners** (primary) — Roche, Takeda, Janssen, AbbVie, Lilly, BMS, argenx, ViiV and others license ENHANZE or Hypercon to improve delivery of their injectable therapies. - **U.S. pharmaceutical distributors** (primary) — Wholesalers such as Cardinal Health, McKesson and Cencora distribute XYOSTED and Hylenex into retail, specialty and institutional channels. - **Hospitals and surgery centers** (secondary) — Buy Hylenex recombinant to support formulary use and clinical workflows in procedural settings. - **Specialty pharmacies and end-user prescription channels** (secondary) — Support fulfillment of XYOSTED and other prescriptions where direct pharmacy access matters. - **Government and VA purchasers** (emerging) — Purchase XYOSTED through contracted distribution channels for eligible patients and institutions. - Biopharma partners licensing ENHANZE for subcutaneous delivery - Hospitals and surgery centers using Hylenex recombinant - Wholesale distributors buying XYOSTED for pharmacies and end users - Specialty pharmacies fulfilling selected prescriptions - Government and VA channels purchasing XYOSTED - Patients and prescribers using testosterone and supportive care products ## Geography Halozyme is headquartered and operationally anchored in the United States, with key facilities in Minnetonka, Minnesota and Boston, Massachusetts. Commercial revenue is generated globally through partner products launched in multiple geographies, while proprietary product sales are concentrated in the U.S. distribution system. The company also relies on international manufacturing and packaging partners, which creates cross-border supply-chain exposure. - U.S. headquarters and core operations in Minnesota and Massachusetts - U.S. proprietary sales through wholesale and specialty distribution - Partner royalties come from global launches across multiple regions - International manufacturing and packaging partners support supply - Commercial exposure spans Europe, China and Japan through partner products ## Strategy Halozyme is focused on expanding the installed base of ENHANZE and Hypercon partner products while growing royalty streams from already launched therapies. It is also using acquisitions and device programs to diversify revenue beyond a single technology platform, while continuing to invest in manufacturing, IP protection and partner scale-up. - **Grow ENHANZE partner product launches** (medium-term) — Royalty growth depends on more partner therapies reaching commercialization and gaining uptake. - **Expand and diversify technology platforms** (medium-term) — New delivery technologies and acquisitions reduce dependence on a single platform and broaden future revenue sources. - **Scale manufacturing and supply chain capability** (short-term) — Commercial growth requires reliable supply of rHuPH20, devices and partner components across multiple vendors. - Expand ENHANZE partner launches to grow royalty and milestone income - Scale bulk rHuPH20 supply as partner demand increases - Develop new versions of rHuPH20 and auto-injector devices - Protect and enforce intellectual property around delivery technologies - Use acquisitions to diversify revenue sources and technology base - Increase manufacturing validation and partner commercialization support ## Risks Halozyme’s business is concentrated in a small number of technology platforms and partner programs, so partner clinical, regulatory or commercial setbacks can quickly affect revenue growth. The company also faces product safety, intellectual property, supply-chain and acquisition-integration risks, all of which are amplified by its reliance on third-party manufacturers and global commercialization partners. - **Partner commercialization risk** [high] — Royalties and milestones depend on partner products reaching approval and sustaining sales growth. - **Regulatory approval delays** [high] — Clinical, manufacturing or FDA issues can delay launches and reduce milestone timing. - **Product safety and recall risk** [high] — Adverse events can trigger label changes, additional studies, recalls or liability claims. - **Intellectual property risk** [medium] — The business model depends on defending patents and exclusivity around delivery technologies. - **Supply-chain and manufacturing concentration** [medium] — Multiple third-party suppliers and packagers are needed for commercial product continuity. - **Acquisition integration risk** [medium] — Recent acquisitions must be integrated successfully to create expected diversification and value. - Revenue depends heavily on partner product launches and sales uptake - Regulatory delays can slow approvals for partner or proprietary products - Adverse events or recalls could hurt approvals and commercial use - IP disputes could weaken protection around ENHANZE and device tech - Third-party manufacturing and logistics create supply-chain exposure - Acquisitions may not deliver expected diversification or returns ## Accounting Halozyme’s results are sensitive to revenue recognition across royalties, milestones, product sales and collaboration arrangements, which can create timing differences between cash receipts and reported revenue. Investors should also watch fair-value estimates for contingent consideration from acquisitions and impairment testing for goodwill and intangibles, because these judgments can materially affect earnings and balance-sheet values. - **Revenue recognition for royalties, milestones and product sales** — Affects quarter-to-quarter comparability and reported growth rates - **Contingent consideration fair value** — Quarterly remeasurement can move operating results - **Goodwill and intangible asset impairment** — Could create non-cash charges if expected cash flows decline - Revenue recognition differs across royalties, milestones and product sales - Milestone timing can create lumpy quarterly revenue - Contingent consideration is remeasured using Level 3 estimates - Goodwill and intangibles are tested for impairment annually - Acquisition accounting can materially affect reported assets and earnings --- *Last updated: 2026-09-24T11:50:44.057670+00:00*